Spliceosome

Vernal Biosciences Launches to Democratize Access to High Quality mRNA Manufacturing

Retrieved on: 
Monday, July 12, 2021
Health, Medical devices, Genetics, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Nucleic acids, RNA, Gene expression, Messenger RNA, Spliceosome, Vernal Biosciences, Vermont Seed Capital Fund, LP, VERNAL BIOSCIENCES, VERMONT SEED CAPITAL FUND, LP

He brings a deep understanding of the mRNA manufacturing value-chainincluding mRNA design and specifications, regulatory expectations, and quality product profilesto improve Vernal clients odds of success through a highly adaptable and well-characterized manufacturing process.

Key Points: 
  • He brings a deep understanding of the mRNA manufacturing value-chainincluding mRNA design and specifications, regulatory expectations, and quality product profilesto improve Vernal clients odds of success through a highly adaptable and well-characterized manufacturing process.
  • We are inspired to realize the potential of mRNA, a validated and revolutionary medicines modality, through democratizing access to unparalleled mRNA manufacturing technologies, said Christian Cobaugh, founder and CEO of Vernal.
  • Equal access to high purity mRNA manufacturing will encourage growth in innovation, competition, and collaboration, accelerating the clinical impact of mRNA as a foundational therapeutic modality.
  • Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.

eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®

Retrieved on: 
Wednesday, June 23, 2021
Branches of biology, Virotherapy, Biology, Molecular genetics, Life sciences, RNA, Gene expression, Messenger RNA, Spliceosome, Immunotherapy, Immunogenicity, Viral vector

This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy ( LMCT ) of the VUB.

Key Points: 
  • This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy ( LMCT ) of the VUB.
  • "We have already demonstrated that TriMix has a benign safety profile and promotes high mRNA expression levels," comments Steven Powell, CEO, eTheRNA.
  • "TetraMix will now be integrated into our programs to engineer new generation mRNA immunotherapies offering even greater efficacy and immunogenicity."
  • Technologies such as mRNA, lentiviral vectors, and single domain antibodies (better known as nanobodies) are employed for these purposes.

eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®

Retrieved on: 
Wednesday, June 23, 2021
Branches of biology, Virotherapy, Biology, Molecular genetics, Life sciences, RNA, Gene expression, Messenger RNA, Spliceosome, Immunotherapy, Immunogenicity, Viral vector

This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy ( LMCT ) of the VUB.

Key Points: 
  • This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy ( LMCT ) of the VUB.
  • "We have already demonstrated that TriMix has a benign safety profile and promotes high mRNA expression levels," comments Steven Powell, CEO, eTheRNA.
  • "TetraMix will now be integrated into our programs to engineer new generation mRNA immunotherapies offering even greater efficacy and immunogenicity."
  • Technologies such as mRNA, lentiviral vectors, and single domain antibodies (better known as nanobodies) are employed for these purposes.

Dave Johnson Joins Biosplice Therapeutics Board of Directors

Retrieved on: 
Monday, June 21, 2021
Life sciences, Branches of biology, Biotechnology, Gene expression, Messenger RNA, Protein biosynthesis, RNA, Spliceosome, Regulus Therapeutics, United Therapeutics

SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board.

Key Points: 
  • SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board.
  • Dave Johnson brings more than 25 years of biopharmaceutical experience.
  • Mr. Johnson also currently serves as Chairman of Aura Biosciences, Inc. and as a director of Zentalis Pharmaceuticals (NASDAQ: ZNTL).
  • Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.

Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research

Retrieved on: 
Thursday, May 13, 2021
Life sciences, Branches of biology, Biology, RNA splicing, Gene expression, Spliceosome, Spinal muscular atrophy, Biotechnology, Biogen, Splice, RNA

and NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Envisagenics today announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases.

Key Points: 
  • and NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Envisagenics today announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases.
  • Envisagenics and Biogen recognize the power of RNA splicing to aid in the discovery of potential therapeutics,\xe2\x80\x9d said Maria Luisa Pineda, Ph.D., chief executive officer of Envisagenics.
  • Through this collaboration, Biogen will gain access to SpliceCore\xe2\x80\x99s database of approximately seven million potential RNA splicing errors, which is the largest database of splicing errors in the world.
  • This will provide Biogen with a broader lens to evaluate splicing events that may be targeted for therapeutic gain.

Christopher Rohde, Ph.D. to Join Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

Retrieved on: 
Thursday, May 13, 2021
Biotechnology, Pharmaceutical, Health, Branches of biology, New York City, Biology, Gene expression, Messenger RNA, Protein biosynthesis, RNA, Spliceosome, BioScience, Brooklyn

Brooklyn ImmunoTherapeutics acquired an exclusive license for the mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited.

Key Points: 
  • Brooklyn ImmunoTherapeutics acquired an exclusive license for the mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited.
  • His work is described in numerous peer-reviewed publications, and has been covered by Technology Review, Nature, Bioscience Magazine, Analytical Chemistry, The Economist, and many other publications.
  • In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit.
  • Forward-looking statements are made based on information available to Brooklyn on the date of this press release, and Brooklyn assumes no obligation to update the information contained in this press release.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210513005303/en/\n'

Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors

Retrieved on: 
Tuesday, April 20, 2021
Nucleic acids, Life sciences, Branches of biology, Gene expression, RNA splicing, Spliceosome, DNA sequencing, Illumina, Inc., Microarrays, Biosplice Therapeutics, Royalty Pharma, Messenger RNA

b'SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (\xe2\x80\x9cBiosplice\xe2\x80\x9d), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to its board.

Key Points: 
  • b'SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (\xe2\x80\x9cBiosplice\xe2\x80\x9d), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to its board.
  • New directors comprise Troy Cox, former CEO of Foundation Medicine, Susannah Gray, former EVP and CFO of Royalty Pharma Management, and Karen McGinnis, former VP and CAO of Illumina.\n\xe2\x80\x9cWe are honored to have this caliber of experience and leadership join our new board at Biosplice,\xe2\x80\x9d said Osman Kibar, PhD, Founder and Executive Chairman of Biosplice.
  • Ms. Gray also serves as a director of Maravai LifeSciences (NASDAQ: MRVI) and 4D Molecular Therapeutics (NASDAQ: FDMT).\nKaren McGinnis has over 20 years of experience in executive operational and finance roles at international public companies.
  • Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing.

PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar

Retrieved on: 
Wednesday, April 7, 2021
Biotechnology, PTC Therapeutics, South Plainfield, New Jersey, Gene expression, Spliceosome, PTC, Huntington, RNA splicing, Software, Companies, Technology

SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ --PTC Therapeutics, Inc.(NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T.

Key Points: 
  • SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ --PTC Therapeutics, Inc.(NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T.
  • The Huntington Disease Deep Dive will provide an overview of PTC's splicing platform and the identification of molecules that have selectivity and specificity.
  • PTC will highlight its Huntington program and the potential advantages of an orally bioavailable compound.
  • PTC will discuss in detail the splicing modifier, PTC518, that is in an ongoing Phase 1 clinical trial.

Maravai LifeSciences Expands Its Intellectual Property Portfolio

Retrieved on: 
Wednesday, February 10, 2021
Branches of biology, Biology, Life sciences, RNA, Vaccination, Messenger RNA, Protein biosynthesis, Spliceosome, Vaccine

This patent is the third U.S. patent that has issued to the company related to the CleanCap technology.

Key Points: 
  • This patent is the third U.S. patent that has issued to the company related to the CleanCap technology.
  • Capping is a critical process in creating viable mRNA constructs that remain biologically active without eliciting immune responses, explains Mike Houston, Ph.D., Chief Scientific Officer of Maravai.
  • Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and to support research on human diseases.
  • Contact Information: Media Contact: Sara Michelmore MacDougall +1 781-235-3060 [email protected] Investor Contact: Deb Hart Maravai LifeSciences + 1 858-988-5917 [email protected]

OliX Pharmaceuticals Launches New Subsidiary to Develop mRNA Vaccines and Therapeutics

Retrieved on: 
Monday, February 8, 2021
Branches of biology, RNA, Life sciences, Biology, Gene expression, Molecular genetics, Messenger RNA, Protein biosynthesis, Spliceosome, RNA interference, Pfizer, Arcturus Therapeutics

(KOSDAQ: 226950), a leading developer of RNAi therapeutics, has announced the establishment of mCureX Therapeutics, Inc., a subsidiary focused on the research and development of messenger RNA (mRNA) vaccines and therapeutics.

Key Points: 
  • (KOSDAQ: 226950), a leading developer of RNAi therapeutics, has announced the establishment of mCureX Therapeutics, Inc., a subsidiary focused on the research and development of messenger RNA (mRNA) vaccines and therapeutics.
  • mRNA technology has been used in two COVID-19 vaccines recently granted Emergency Use Authorization by the U.S. Food and Drug Administration.
  • mRNA represents a rapidly advancing and nimble platform that complements our existing RNAi drug development platform as we develop therapeutics and vaccines for urgent and unmet medical needs in Korea and beyond.
  • He developed the foundational technology of mRNA 5-capping, which is used in the COVID-19 mRNA vaccines developed by Pfizer and BioNTech.